Robert Wenham, MD, MS, FACS, On Advantages of FSHR-CER T for Ovarian Cancer

Video

The chair of gynecologic oncology at Moffitt Cancer Center discussed advantages of targeting follicle stimulating hormone receptor with cell therapy for ovarian cancer.

“Follicle stimulating hormone receptor’s target is ovarian tissue. There was a little bit of expression that was seen on testis and since we are treating women with ovarian cancer, that's not a concern for us at all. So, I think that this specificity will allow us to give cell doses that will really be selectingfor the targeted tissue.”

Anixa is developing a chimeric endocrine receptor T-cell (CER-T) therapy targeting follicle stimulating hormone receptor (FSHR) for the potential treatment of ovarian cancer. The therapy is currently being evaluated in a phase 1 study (NCT05316129) with Anixa’s collaborator, Moffitt Cancer Center, in Tampa, Florida.

The study dosed its first patient with ovarian cancer in August 2022. The dose-escalation study will enroll up to 48 participants to determine the maximum tolerated dose of the CER-T therapy and to evaluate its safety profile.

CGTLive spoke with principal investigator Robert Wenham, MD, MS, FACS, chair, gynecologic oncology, Moffitt Cancer Center, to learn more about the treatment landscape and unmet needs of ovarian cancer. He discussed how the landscape was stagnant until recently and how more precise targeting is needed to achieve more efficacy in treating this type of cancer.

REFERENCE
Anixa Biosciences announces treatment of first patient in its ovarian cancer CAR-T clinical trial. News release. August 15, 2022. https://ir.anixa.com/press-releases/detail/999/anixa-biosciences-announces-treatment-of-first-patient-in

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.